TICKERNERD
Menu
LGVNLGVNHealthcare · Biotechnology

LGVN Stock Forecast: Longeveron, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$0.84
+1.96% on the day

The 3 Wall Street analysts covering Longeveron, Inc. hold a median 12-month price target of $8 — +847.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 33 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$26.9M
Ticker Nerd rank
33 / 100
Median analyst target
$8.00
Analysts covering
3
Total return, dividends reinvested
1W
+14.1%
1M
+38.0%
YTD
+66.9%
1Y
+5.5%
From 52W high
−27.2%
From 52W low
+74.5%
$0.48
$1.16
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LGVN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Longeveron, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
33 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
87
Accruals
84
Issuance
46
Volatility
38
Momentum
37
Quality
36
Revisions
34
Growth
28
Value
17

Size (87): Smaller than most of the companies we track.

Value (17): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LGVN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LGVN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Oct 25Jan 26Apr 26Jul 26LGVNHigh $10.45Median $8.00Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says3 analysts
2 Buy1 Hold0 Sell
Low $3.00Median $8.00High $10.45

The green dot is the last close — the median target sits +847.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 May 2026Maxim GroupDowngradeHold—
4 May 2026HC Wainwright & Co.MaintainsBuy$10 → $8.00
15 Aug 2025Roth CapitalMaintainsBuy—
21 Mar 2025HC Wainwright & Co.ReiteratesBuy—
3 Mar 2025HC Wainwright & Co.ReiteratesBuy—
5 Dec 2024Roth MKMInitiatesBuy—
25 Nov 2024HC Wainwright & Co.ReiteratesBuy—
4 Nov 2024HC Wainwright & Co.ReiteratesBuy—
4 Sept 2024HC Wainwright & Co.ReiteratesBuy—
27 Aug 2024Maxim GroupMaintainsBuy—
15 Aug 2024HC Wainwright & Co.ReiteratesBuy—
31 July 2024HC Wainwright & Co.ReiteratesBuy—
29 July 2024HC Wainwright & Co.MaintainsBuy—
17 May 2024HC Wainwright & Co.ReiteratesBuy—
29 Apr 2024HC Wainwright & Co.MaintainsBuy—
4 Dec 2023HC Wainwright & Co.InitiatesBuy—
1 June 2023EF HuttonAssumesBuy$13
16 May 2023EF HuttonReiteratesBuy—
9 May 2023EF HuttonReiteratesBuy—
27 Mar 2023EF HuttonReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LGVN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

LGVN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Longeveron, Inc. (LGVN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2.9×

Cheaper than 68% of US stocks

Price / sales
22.7×

Cheaper than 9% of US stocks

Price / book
2.6×

Cheaper than 39% of US stocks

EV / EBITDA
−0.8×

Cheaper than 65% of US stocks

Growth & margins
Revenue growth (YoY)
−9.2%

Higher than 16% of US stocks

Earnings growth (YoY)
4.5%

Higher than 41% of US stocks

Gross margin
66.3%

Higher than 80% of US stocks

Operating margin
−2150.2%

Higher than 4% of US stocks

Net margin
67.0%

Higher than 97% of US stocks

Returns & dividend
Return on equity
−203.6%

Higher than 7% of US stocks

Return on assets
−90.9%

Higher than 3% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

LGVN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
LGVNLongeveron, Inc.$26.9M
33
QNTMQuantum BioPharma Ltd.$27.0M
43
ATOSAtossa Therapeutics, Inc.$25.3M
23
GRDXGridAI Technologies Corp.$25.3M
38
DYAIDyadic International, Inc.$27.6M
19
CVMCEL-SCI Corp.$24.8M
34
TVRDTvardi Therapeutics, Inc.$24.8M
28

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Longeveron, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LGVN news & analysis

Longeveron Appoints Nirav Jhaveri as Chief Financial Officer

GlobeNewsWire · 19 Aug 2026neutral

Longeveron announced the appointment of Nirav Jhaveri, CFA, as Chief Financial Officer, principal financial officer and principal accounting officer, succeeding Marie Washburn who had stepped into the role after the prior CFO's retirement. Jhaveri brings over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector.

Why it matters — A new CFO with extensive biotech and capital markets experience joins Longeveron's executive leadership team, which could be relevant to investors following the company's financial management and strategic direction.

Longeveron Inc. (LGVN) Q2 2026 Earnings Call Transcript

Seeking Alpha · 13 Aug 2026neutral

Longeveron Inc. held its Q2 2026 earnings call, and Seeking Alpha published the corresponding transcript of the management discussion.

Why it matters — LGVN watchers can review the transcript for the company's own commentary on its second-quarter results and operations.

Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update

GlobeNewsWire · 12 Aug 2026neutral

Longeveron reported financial results for the quarter ended June 30, 2026, and provided a business update. The company said it remains on track for September 2026 top-line results from its Phase 2b clinical trial (ELPIS II) of laromestrocel for hypoplastic left heart syndrome, noted its selection as a Finalist and Milestone 2 Awardee for the XPRIZE Healthspan competition, and announced three new independent directors joining its Board.

Why it matters — LGVN watchers would care because the update confirms progress on its key Phase 2b trial timing for laromestrocel while also highlighting new recognition and board changes that could signal the company's trajectory.

Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026

GlobeNewsWire · 3 Aug 2026neutral

Longeveron Inc. (NASDAQ: LGVN) announced that it will report its 2026 second quarter financial results and provide a business update on Wednesday, August 12, 2026, after U.S. financial markets close, and will host a conference call at that time.

Why it matters — A Longeveron watcher would care because this scheduled update will offer the next official insight into the company's financial standing and business progress.

FAQ

Frequently asked questions about LGVN stock

What is the LGVN stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Longeveron, Inc. have a median 12-month price target of $8, with estimates ranging from $3 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LGVN stock a buy right now?

Of the 3 analysts covering Longeveron, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Longeveron, Inc. 33 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LGVN?

As at 22 Aug 2026, Longeveron, Inc. ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (87 of 100).

Will LGVN stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +847.4% from the last close, and Ticker Nerd's factor model ranks Longeveron, Inc. 33 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LGVN stock forecast for 2030?

No analyst covering Longeveron, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LGVN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $10 over the next 12 months.

How has LGVN stock performed over the past year?

Longeveron, Inc. returned +5.5% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Longeveron, Inc. do?

Longeveron Inc. is a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions.

What is the latest news on LGVN?

The most recent item we track (GlobeNewsWire, 19 Aug 2026): "Longeveron Appoints Nirav Jhaveri as Chief Financial Officer". Longeveron announced the appointment of Nirav Jhaveri, CFA, as Chief Financial Officer, principal financial officer and principal accounting officer, succeeding Marie Washburn who had stepped into the role after the prior CFO's retirement. Jhaveri brings over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector.

Company

About Longeveron, Inc.

Longeveron Inc. is a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. Its lead investigational product, Lomecel-B (also known as laromestrocel), is an allogeneic mesenchymal stem cell formulation derived from the bone marrow of young, healthy adult donors. This therapy promotes tissue repair, regeneration, reduces inflammation, and supports healing through multiple mechanisms of action. Longeveron Inc. focuses on key pipeline indications including hypoplastic left heart syndrome, a rare pediatric heart condition; Alzheimer's disease; and aging frailty. The company advances these programs through ongoing Phase 2 clinical trials and has received FDA designations to support development. Operating in the regenerative medicine sector, Longeveron Inc. sources materials from established bone marrow suppliers and conducts research primarily in the United States, with activities extending to Japan. Founded in 2014 and headquartered in Miami, Florida, it plays a role in addressing unmet needs in chronic diseases affecting healthspan.

CEO Mr. Stephen H. Willard Esq. · 38 employees · United States · https://longeveron.com